Kyle Jenne
Vermögen: 2 Mio $ am 31.05.2026
Vermögen: 2 Mio $ am 31.05.2026
Kyle Jenne is currently Chief Global Product Strategy Officer & EVP at Ionis Pharmaceuticals, Inc. since 2024.
Former roles include Chief Executive Officer & Director at Elsie Biotechnologies Inc., Chief Commercial Officer & Executive VP at Ionis Pharmaceuticals, Inc., and Senior Vice President-US Commercial at Akcea Therapeutics, Inc. from 2017 to 2019.
Education includes undergraduate studies at Arizona State University.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 16.04.2026 | 23’713 ( 0.01% ) | 2 Mio $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| IONIS PHARMACEUTICALS, INC. | Corporate Officer/Principal | 29.02.2024 |
| Unternehmen | Position | Ende |
|---|---|---|
| IONIS PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Elsie Biotechnologies Inc.
Elsie Biotechnologies Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops oligonucleotide therapeutics | Vorstandsvorsitzender | - |
| AKCEA THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 4 |
|---|---|
Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops antisense drugs | Health Technology |
Arizona State University
Arizona State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Akcea Therapeutics, Inc.
Akcea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops drugs for cardiometabolic lipid disorders | Health Technology |
Elsie Biotechnologies Inc.
Elsie Biotechnologies Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops oligonucleotide therapeutics | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen